Manufacture of pharmaceutical preparations (PKD 21.20.Z)
This subclass includes:
- manufacture of medicinal products:
- of various blood fractions, including fractions containing antibodies,
- vaccines,
- various medicines, including homeopathic preparations,
- manufacture of chemical contraceptives for external use and hormonal contraceptives,
- manufacture of medicinal diagnostic preparations, including pregnancy tests,
- manufacture of radioactive diagnostic substances used in vivo,
- manufacture of pharmaceutical products for advanced cell and gene therapy,
- manufacture of impregnated or coated absorbent cotton, gauze, bandages, dressings and the like with medicinal substances,
- preparation of plant products (crushing, sorting, grinding) for pharmaceutical use,
- manufacture of medicines and vaccines based on viral vectors,
- manufacture of pharmaceutical products for veterinary medicinal products.
This subclass excludes:
- manufacture of herbal teas (mint, verbena, chamomile and the like), classified in 10.83.Z,
- manufacture of probiotics, classified in 21.10.Z,
- manufacture of dental fillings and dental cement, classified in 32.50.A,
- manufacture of surgical drapes, classified in 32.50.B,
- wholesale of pharmaceutical and medical products, classified in 46.46.Z,
- retail sale of pharmaceutical products, classified in 47.73.Z,
- research and development in biotechnology concerning pharmaceutical substances and other biotechnological products, classified in 72.10.Z,
- contract packaging of pharmaceutical and medical products, classified in 82.92.Z.
Industry statistics (2025)
Number of companies
Companies
Business turnover
Legal structure
Legal formShare of companiesNumber of companies
- Sp. z o.o.74.6%323
- S.A.8.1%35
- Sp. j.7.2%31
- JDG3.0%13
- Sp. k.2.3%10
- P.S.A.1.8%8
- Cooperative1.4%6
- Other0.9%4
- Foundation0.7%3
Financial results
Median revenue
Ranking
Median revenue compared with other PKD codes.
Top companies by revenue
| # | Company | Legal form | Revenue | Net profit |
|---|---|---|---|---|
| 1 | S.A. | USD 1.25bn | USD 236.49m | |
| 2 | S.A. | USD 615.32m | USD 16.99m | |
| 3 | S.A. | USD 539.49m | USD 53.86m | |
| 4 | sp. z o.o. | USD 527.04m | USD 77.39m | |
| 5 | sp. z o.o. | USD 300.66m | USD 59.18m | |
| 6 | sp. z o.o. | USD 245.99m | USD 33.23m | |
| 7 | S.A. | USD 159.45m | USD 6.68m | |
| 8 | sp. z o.o. | USD 142.78m | USD 34.11m | |
| 9 | S.A. | USD 119.08m | USD 4.98m | |
| 10 | sp. z o.o. | USD 112.36m | USD 2.95m |
Fastest-growing companies
| # | Company | Legal form | Revenue | Y/Y growth |
|---|---|---|---|---|
| 1 | sp. z o.o. | USD 47.06m | +92.4% y/y | |
| 2 | sp. z o.o. | USD 3.81m | +83.9% y/y | |
| 3 | sp. z o.o. | USD 21.37m | +57.8% y/y | |
| 4 | sp. z o.o. | USD 4.24m | +54.9% y/y | |
| 5 | sp. z o.o. | USD 5.96m | +40.1% y/y | |
| 6 | sp. z o.o. | USD 20.12m | +37.3% y/y | |
| 7 | S.A. | USD 71.45m | +34.6% y/y | |
| 8 | sp. z o.o. | USD 4.39m | +32.0% y/y | |
| 9 | sp. z o.o. | USD 2.27m | +28.3% y/y | |
| 10 | sp. z o.o. | USD 24.58m | +26.2% y/y |
Stock market
6 companies from this industry are listed.
| Company | Ticker | Market | Price | Change | Market cap |
|---|---|---|---|---|---|
| CLN | GPW Main Market | PLN 15.56 | -1.52% | USD 209.72m | |
| BIO | GPW Main Market | PLN 3.43 | -0.15% | USD 73.63m | |
| SVE | GPW Main Market | PLN 2.84 | -0.18% | USD 53.88m | |
| PTG | GPW Main Market | PLN 18.90 | -0.53% | USD 27.96m | |
| SCS | NewConnect | PLN 0.51 | 0.00% | USD 5.27m | |
| MUN | NewConnect | PLN 0.28 | -2.43% | USD 3.30m |
Related PKD codes in division 21
FAQ
The primary industry for 433 companies is manufacture of pharmaceutical preparations. 258 entities have filed financial statements.
So far in 2026, 8 new companies with PKD 21.20.Z have been registered. In all of 2025, there were 21 such companies.
So far in 2026, 2 companies with PKD 21.20.Z have been deregistered. In all of 2025, there was 1 such company.
In 2025, the median revenue for PKD 21.20.Z was USD 1.48m and the mean revenue was USD 33.61m, based on 192 financial statements. Averages and medians include only companies that file financial statements, excluding sole proprietorships.
Yes, in 2025, the median net profit was USD 31.02k, an improvement on 2024 (USD 13.03k). Among all 628 industries in Poland, PKD 21.20.Z ranks 185th, putting it in the top 29%.
The most common legal form for PKD 21.20.Z is sp. z o.o., used by 323 companies in this industry (74.6% of the total). In second place is S.A. (35 companies, 8.1%), and in third place – sp. j. (31 companies, 7.2%).





















